There is emerging interest in adaptive platform trials for inflammatory bowel disease. In this Comment, we present the results of a workshop that was convened to consider the opportunities and challenges of developing a platform trial in Crohn’s disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Woodcock, J. & LaVange, L. M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62–70 (2017).
Noor, N. M. et al. Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials. BMJ Open 12, e055615 (2022).
Honap, S. et al. Basket, umbrella, and platform trials: the potential for master protocol-based trials in inflammatory bowel disease. Gastroenterology 167, 636–642.e2 (2024).
Harris, M. S., Wichary, J., Zadnik, M. & Reinisch, W. Competition for clinical trials in inflammatory bowel diseases. Gastroenterology 157, 1457–1461.e2 (2019).
Uzzan, M. et al. Declining enrolment and other challenges in IBD clinical trials: causes and potential solutions. J. Crohns Colitis 17, 1066–1078 (2023).
Din, S. et al. Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 9, 1020–1029 (2024).
Gros, B. et al. Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 9, 1030–1040 (2024).
Sydes, M. R. et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 13, 168 (2012).
Parmar, M. K. B. et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clin. Trials 14, 451–461 (2017).
Noor, N. M. et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol. Hepatol. 9, 415–427 (2024).
Darie, A.-M. et al. BSG 2024 IBD guidelines protocol (standard operating procedures). BMJ Open Gastroenterol. 10, e001067 (2023).
Shaban, N., Sinopoulou, V., Vuyyuru, S., Moran, G. & Gordon, M. DOP02 developing explicit thresholds for outcomes to inform (GRADE) evidence to decision frameworks for inflammatory bowel disease guidelines. J. Crohns Colitis 18, i73–i74 (2024).
Turner, D. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570–1583 (2021).
Acknowledgements
The authors thank individuals at Crohn’s and Colitis UK (K. Nightingale and R. Ainley) and patient research champions from Crohn’s and Colitis UK (S. Andrew and T. Kelly) for their review and valued contributions. The authors also acknowledge advice from additional individuals who were not able to join for this workshop (J. Begun, Australia; P. Irving, UK; and S. Sebastian, UK). There is no specific funding associated with the development of this manuscript. N.M.N. is supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. B.C.-O. and M.K.B.P. are supported by the UK Medical Research Council (MRC) (MC_UU_00004_09).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.M.N. has received educational grants and/or speaker fees from AbbVie, BMS, Celltrion, Dr Falk Pharma, Ferring, Galapagos, Janssen, Eli Lilly, Medfyle, Pfizer, Pharmacosmos, Takeda and Tillotts Pharma AG, all outside of the submitted work. A.L.H. has received consultancy fees from AbbVie, Bristol Myers Squibb, Celltrion, Galapagos, Johnson & Johnson, Takeda, Pfizer and Eli Lilly; has received honoraria from AbbVie, Bristol Myers Squibb, Celltrion, Galapagos, Johnson & Johnson, Takeda, Pfizer and Eli Lilly; and has received support for attending meetings or travel from AbbVie, Bristol Myers Squibb, Celltrion, Galapagos, Johnson & Johnson, Takeda, Pfizer and Eli Lilly, all outside of the submitted work. J.O.L. reports personal fees from AbbVie, Atlantic Healthcare, Bristol Myers Squibb, Celgene, Celltrion, Engytix, Eli Lilly, Ferring, Galapagos, Gilead, GSK, Janssen, MSD, Norgine, Pfizer, Shire and Takeda outside the submitted work; and grants from AbbVie, Ferring, Gilead, Takeda and Shire outside the submitted work. N.A.K. reports personal fees from Amgen, Bristol Myers Squibb, Celltrion, Falk, Galapagos, Janssen, Pfizer, Pharmacosmos, Takeda and Tillotts Pharma outside the submitted work; and reports data monitoring board membership for the BEACON study outside the submitted work. V.J. reports personal fees from AbbVie, Alimentiv (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, Avoro Capital, BMS, Celltrion, Endpoint Health, Enthera, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, Gilde Healthcare, GSK, Genentech, Gilead, Innomar, JAMP, Janssen, Eli Lilly, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Roivant, Sandoz, SCOPE, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, Topivert, Ventyx and Vividion outside the submitted work; and fees from advisory board membership of AbbVie, Alimentiv (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, BMS, Celltrion, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, Gilde Healthcare, GSK, Genentech, Gilead, Innomar, JAMP, Janssen, Eli Lilly, Merck, Metacran, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, SCOPE, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, Topivert, Ventyx and Vividion, all outside the submitted work. G.W.M. declares consultancy fees/grant funding from AbbVie, AstraZeneca and Janssen, all outside the submitted work. The other authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Noor, N.M., Radford, S.J., Choodari-Oskooei, B. et al. Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease. Nat Rev Gastroenterol Hepatol 22, 364–366 (2025). https://doi.org/10.1038/s41575-025-01052-0
Published:
Issue date:
DOI: https://doi.org/10.1038/s41575-025-01052-0
